Answers are grounded in this paper and cite their sources.
Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: